Distamycin A-inducible fragile sites and cancer proneness.
To determine the baseline frequency of autosomal rare fragile sites in cancer patients, we conducted a population cytogenetic study of 370 patients with leukemias, solid tumors, and other neoplastic disorders. Twenty carriers of rare fragile sites were detected in this patient group. The rare autosomal fragile sites were at fra(8)(q24), fra(11)(p15), fra(16)(p12.1), fra(16)(q22), and fra(17)(p12). All of these fragile sites were found to be distamycin A inducible. Compared with a population incidence in healthy subjects (44 of 845, 5.21%), the overall incidence of distamycin A-inducible fragile sites was not higher in the patient group (20 of 370, 5.41%). Analysis of these individual fragile sites and particular diseases, however, suggests that the distamycin A-inducible fragile sites may play a role in the etiology of leukemia, myeloproliferative disorders, and benign tumors.
Hori
T
T
Division of Genetics, National Institute of Radiological Sciences, Chiba, Japan.
Takahashi
E
E
Ishihara
T
T
Minamihisamatsu
M
M
Kaneko
Y
Y
Murata
M
M
D043283:Chromosome Fragile Sites; D002873:Chromosome Fragility; D004198:Disease Susceptibility; D004214:Distamycins / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007621:Karyotyping; D008297:Male; D009369:Neoplasms / Q000235:genetics*; D011758:Pyrroles / Q000494:pharmacology*; D014407:Tumor Cells, Cultured / Q000187:drug effects
D004214:Distamycins; D011758:Pyrroles; C030000:stallimycin